NCT06103825: A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients With Obstructive Sleep Apnea (OSA) |
|
|
| Recruiting | 3 | 204 | RoW | Solriamfetol, Placebo | Ignis Therapeutics (Suzhou) Limited | Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea | 09/24 | 10/24 | | |
